Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FCZJ9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,591.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,591.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Nucala 100 mg/ml auto-injector units. The contract, with an ultimate completion date of February 4, 2026, carries no set-aside designation, indicating the award was made through unrestricted federal competition. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying pharmaceuticals and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's IDC, valued at $499,999,999 with a completion date of December 31, 2036, was awarded on November 13, 2025, and includes a 30-month base period with three 30-month option periods.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the Department of Defense pharmaceutical supply chain, with a product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals supporting diverse therapeutic categories. The company, registered in the System for Award Management since July 2001, competes effectively in federal procurement across multiple product lines and has established consistent contract performance with the Defense Logistics Agency. No subcontractors have been identified in the award documentation, with DMS Pharmaceutical Group serving as the sole prime contractor on this delivery order and broader pharmaceutical supply agreements supporting military medical operations.
Quick answers
Who was awarded contract SPE2DR26FCZJ9?
SPE2DR26FCZJ9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 3, 2026.
How much is contract SPE2DR26FCZJ9 worth?
The government has obligated $11,591 on SPE2DR26FCZJ9.
Is contract SPE2DR26FCZJ9 an order under another contract?
Yes. SPE2DR26FCZJ9 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZJ9 competed?
The extent of competition for SPE2DR26FCZJ9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award